ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IDYA IDEAYA Biosciences Inc

38.11
-0.82 (-2.11%)
Jun 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 524,927
Bid Price 37.43
Ask Price 41.13
News -
Day High 38.86

Low
20.90

52 Week Range

High
47.735

Day Low 37.82
Company Name Stock Ticker Symbol Market Type
IDEAYA Biosciences Inc IDYA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.82 -2.11% 38.11 20:00:00
Open Price Low Price High Price Close Price Prev Close
38.41 37.82 38.86 38.11 38.93
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,613 524,927 $ 38.35 $ 20,132,708 - 20.90 - 47.735
Last Trade Time Type Quantity Stock Price Currency
16:20:00 94 $ 38.11 USD

IDEAYA Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.84B 74.56M - 23.39M -112.96M -1.52 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

IDEAYA Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No IDYA Message Board. Create One! See More Posts on IDYA Message Board See More Message Board Posts

Historical IDYA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week39.3940.6536.8538.48774,446-1.28-3.25%
1 Month40.8942.2035.5738.581,014,402-2.78-6.80%
3 Months45.3245.3235.5740.01736,167-7.21-15.91%
6 Months33.0647.73532.5640.56871,2645.0515.28%
1 Year25.0547.73520.9034.69768,69213.0652.14%
3 Years21.0147.7358.1425.66531,10917.1081.39%
5 Years10.6247.7352.9524.04370,51027.49258.85%

IDEAYA Biosciences Description

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Your Recent History

Delayed Upgrade Clock